GLIOMATCH is a Horizon Europe project with the ambition of pioneering targeted brain cancer treatment. KU Leuven leads the GLIOMATCH consortium uniting over a dozen pan-European partners from 10 different member states.
KU Leuven is home to the Laboratory for Precision Cancer Medicine, attached to the Translational Cell and Tissue Research Unit of the Department of Imaging and Pathology and the Leuven Institute for Single-cell Omics, focused on precision matching of cancer treatments with patients.
In alignment with Europe’s Beating Cancer Plan, GLIOMATCH addresses the EU Cancer Mission‘s four objectives: understanding cancer, prevention and early detection, diagnosis and treatment, and quality of life for patients and their families
Brain tumours are amongst the most lethal forms of cancer types, causing profound distress for individuals and their families and imposing a burden on communities and healthcare systems. By making technology for customised treatments available to clinicians, GLIOMATCH aims to alleviate this burden.
The prospects for patients of all ages suffering from glioblastoma are bad and have barely improved over the past three decades.
Patients and tumours are extremely heterogeneous and clinicians lack valuable information required for matching patients with the most effective treatments.
A platform for clinicians, which continuously integrates and evaluates years worth of data from glioblastoma patients, can significantly improve patient care.
Prof. Frederik De Smet from KU Leuven,
GLIOMATCH project coordinator
The GLIOMATCH project kick-off meeting took place from 25-27 March 2024 and was hosted by KU Leuven, the project coordinator, at the Faculty Club in Leuven, Belgium. This marks the first in-person gathering of the project’s 14 partner institutions.
According to the World Health Organisation, cancer ranks as the world’s second-leading cause of death. Brain tumours have particularly high mortality rates. The GLIOMATCH project is set to rewrite this narrative.
Under the coordination of KU Leuven, the multidisciplinary consortium will be working on pioneering personalised therapies for brain cancer patients.
